General Pharmacology Practice Questions

Q: Which of the following drugs is an inhibitor of cytochrome P450 enzymes?

Ketoconazole. **Explanation:** The cytochrome P450 (CYP450) system is a superfamily of enzymes primarily located in the liver responsible for the oxidative metabolism of many drugs [3]. Drugs that interact with these enzymes are classified as either **Inducers** (increase enzyme activity, decreasing plasma levels of co-administered drugs) or **Inhibitors** (decrease enzyme activity, increasing plasma levels and toxicity of co-administered drugs). **1. Why Ketoconazole is Correct:** **Ketoconazole** is a potent **enzyme inhibitor** [2]. It binds to the heme iron of the CYP450 system (specifically CYP3A4), preventing the oxidation of other substrates [1]. This leads to increased serum concentrations of drugs like warfarin, phenytoin, and statins, potentially causing toxicity [5]. **2. Why the Other Options are Incorrect:** * **Rifampicin:** A powerful **enzyme inducer** [4]. It is a classic example used in TB treatment that reduces the efficacy of oral contraceptives and warfarin. * **Phenytoin:** An anticonvulsant that acts as an **enzyme inducer** [4]. * **Phenobarbitone:** One of the most potent **enzyme inducers** known; it increases the synthesis of CYP450 enzymes by increasing mRNA transcription [4]. **Clinical Pearls for NEET-PG:** To remember these for the exam, use these popular mnemonics: * **Enzyme Inhibitors (VITAMIN K):** **V**erapamil, **I**soniazid, **T**rimethoprim, **A**miodarone, **M**acrolides (except Azithromycin), **I**ndinavir, **N**etwork (Azoles like **Ketoconazole**), **K**etoconazole, and **C**imetidine/Ciprofloxacin/Grapefruit juice. * **Enzyme Inducers (GPRS Cell Phone):** **G**riseofulvin, **P**henytoin, **R**ifampicin, **S**moking, **C**arbamazepine, **P**henobarbitone. * **Note:** Valproate is an inhibitor, whereas most other older anticonvulsants are inducers.

Q: Cyproheptadine acts on which of the following receptors?

D2. **Explanation:** Cyproheptadine is a unique pharmacological agent known for its **multi-receptor antagonist** properties. While it is primarily classified as a first-generation antihistamine, its clinical utility and side-effect profile are dictated by its action on several receptor systems. **1. Why Option A (D2) is the Correct Answer (in the context of this specific question):** Cyproheptadine acts as an antagonist at **H1, 5-HT2A, and Muscarinic** receptors. However, it **does not** have significant activity at **Dopamine (D2) receptors**. In NEET-PG "Except" or "Which of the following" questions, identifying the receptor *not* blocked by the drug is a common testing pattern. Therefore, D2 is the correct choice as it is the outlier. **2. Analysis of Other Options:** * **Option B (H1):** Cyproheptadine is a potent **H1-receptor antagonist**, used to treat allergic rhinitis and urticaria. * **Option C (Muscarinic):** Like most first-generation antihistamines, it possesses significant **anticholinergic (anti-muscarinic)** activity, leading to side effects like dry mouth and urinary retention. * **Option D (5-HT2A):** This is a high-yield fact. Cyproheptadine is a powerful **5-HT2A antagonist**. This property makes it the drug of choice for managing **Serotonin Syndrome**. **Clinical Pearls for NEET-PG:** * **Serotonin Syndrome:** Cyproheptadine is the specific antidote. * **Appetite Stimulant:** Due to its 5-HT2 blockade in the hypothalamus, it is used off-label to stimulate appetite in children and patients with cachexia. * **Other Uses:** It is used in the prophylaxis of **Migraine** and the management of **Post-gastrectomy Dumping Syndrome**. * **Key Contraindication:** Due to its anticholinergic effects, it should be avoided in patients with **Glaucoma** and **BPH**.

Q: Sufentanil is a/an:

Analgesic. **Explanation:** **Correct Option: A (Analgesic)** Sufentanil is a potent synthetic opioid derivative of **fentanyl**. It acts primarily as a selective **$\mu$-opioid receptor agonist** in the central nervous system. Its primary clinical use is as an analgesic and anesthetic adjuvant. It is highly lipid-soluble, allowing it to cross the blood-brain barrier rapidly, providing immediate pain relief. **Why incorrect options are wrong:** * **B. Antibiotic:** Sufentanil has no antimicrobial properties; it does not inhibit bacterial cell wall synthesis, protein synthesis, or DNA replication. * **C. Anticholinergic:** Sufentanil does not block acetylcholine receptors. In fact, opioids can sometimes cause parasympathetic effects (like miosis) rather than anticholinergic effects (like mydriasis). * **D. Newer antihistaminic:** It does not antagonize H1 or H2 receptors. While some opioids (like morphine) cause histamine release, sufentanil is a synthetic opioid that typically causes minimal histamine release compared to natural opiates. **High-Yield Clinical Pearls for NEET-PG:** * **Potency:** Sufentanil is approximately **5 to 10 times more potent than fentanyl** and nearly **500 to 1,000 times more potent than morphine**. * **Context-Sensitive Half-life:** It has a shorter context-sensitive half-life than fentanyl for infusions lasting up to 8 hours, making it favorable for prolonged surgical procedures. * **Safety Profile:** It provides greater hemodynamic stability compared to other opioids, making it a preferred choice in cardiac anesthesia. * **Antidote:** Like all opioids, its effects (including respiratory depression) can be reversed by **Naloxone**.

Q: What is the primary purpose of pharmacovigilance?

To monitor drug toxicity. **Explanation:** **Pharmacovigilance (PV)** is defined by the WHO as the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems [1]. 1. **Why Option A is Correct:** The primary goal of pharmacovigilance is to ensure patient safety by monitoring the **safety profile** of drugs after they have been released into the market (Phase IV: Post-marketing surveillance) [1]. It identifies previously unrecognized adverse drug reactions (ADRs), quantifies their risks, and monitors drug toxicity over long-term use in a diverse population [1]. 2. **Why Other Options are Incorrect:** * **Option B:** Monitoring unauthorized manufacture is a regulatory and legal function of bodies like the CDSCO or FDA, not a clinical pharmacovigilance activity. * **Option C:** Monitoring students is an academic or administrative task unrelated to pharmacology. * **Option D:** Drug cost monitoring (Pharmacoeconomics) evaluates the cost-benefit ratio of therapies but does not fall under the safety-centric scope of pharmacovigilance. **High-Yield Clinical Pearls for NEET-PG:** * **Phase IV Clinical Trial:** Pharmacovigilance is the hallmark of Phase IV trials. It is essential because rare ADRs (occurring in <1 in 10,000) are often missed in Phase I-III trials due to small sample sizes. * **Pharmacovigilance Programme of India (PvPI):** Launched in 2010; the National Coordinating Centre is the **Indian Pharmacopoeia Commission (IPC)**, Ghaziabad. * **Uppsala Monitoring Centre (UMC):** Located in Sweden, it is the WHO's international headquarters for ADR monitoring. * **Thalidomide Tragedy:** The catalyst for modern pharmacovigilance regulations worldwide [1].

Q: Which of the following drugs is not metabolized by acetylation?

Metoclopramide. **Explanation:** The question tests your knowledge of **Phase II metabolic reactions**, specifically **Acetylation**. This process is mediated by the enzyme **N-acetyltransferase (NAT)**. **Why Metoclopramide is the correct answer:** Metoclopramide is primarily metabolized in the liver via **Glucuronidation** and **Sulfation** (Phase II reactions), as well as oxidation. It does not undergo acetylation. It is a dopamine (D2) antagonist used as a prokinetic and antiemetic. **Why the other options are incorrect:** Options A, B, and C are classic examples of drugs metabolized by acetylation. A useful mnemonic to remember these is **"SHIP"**: * **S – Sulfonamides** (and **Dapsone**, which is a sulfone) * **H – Hydralazine** * **I – Isoniazid (INH)** * **P – Procainamide** * **Isoniazid (INH):** The prototype drug for acetylation. It is metabolized by NAT2. * **Dapsone:** Used in leprosy; its metabolite monoacetyl dapsone is a marker of acetylation status. * **Hydralazine:** An antihypertensive that carries a high risk of drug-induced lupus in certain patients. **High-Yield Clinical Pearls for NEET-PG:** 1. **Genetic Polymorphism:** Acetylation shows bimodal distribution in the population, dividing individuals into **Fast Acetylators** and **Slow Acetylators**. 2. **Slow Acetylators:** These individuals are at a higher risk of toxicity from "SHIP" drugs. Specifically, they are prone to **Drug-Induced Lupus Erythematosus (DILE)** (especially with Hydralazine and Procainamide) and **Peripheral Neuropathy** (with Isoniazid). 3. **Fast Acetylators:** They may require higher doses of these drugs to achieve therapeutic levels and are at a higher risk of **Hepatotoxicity** with Isoniazid due to the rapid formation of the metabolite acetylhydrazine.

Q: Which of the following is a P-Glycoprotein inhibitor?

Ketoconazole. **Explanation:** **P-glycoprotein (P-gp)** is an ATP-dependent efflux transporter found in the gut lining, blood-brain barrier, and renal tubules. It pumps drugs out of cells, thereby limiting their absorption and increasing their elimination. **Why Ketoconazole is Correct:** **Ketoconazole** is a potent **inhibitor** of both CYP3A4 and P-glycoprotein. By inhibiting P-gp, it reduces the efflux of substrate drugs (like Digoxin or Cyclosporine), leading to increased plasma concentrations and potential toxicity. Most drugs that inhibit CYP3A4 also tend to inhibit P-gp. **Why the Other Options are Incorrect:** * **Rifampicin:** This is a classic **inducer** of P-gp. It increases the expression of the transporter, leading to decreased plasma levels of P-gp substrates. * **Phenytoin:** Similar to Rifampicin, Phenytoin is a broad-spectrum microsomal enzyme **inducer** and also induces P-gp. * **Griseofulvin:** This antifungal agent acts as an enzyme **inducer**. It does not inhibit P-gp. **High-Yield Clinical Pearls for NEET-PG:** * **Key P-gp Inhibitors:** Verapamil (most potent), Quinidine, Ketoconazole, Itraconazole, Erythromycin, and Amiodarone. * **Key P-gp Inducers:** Rifampicin, St. John’s Wort, Phenytoin, and Carbamazepine. * **Important Substrate:** **Digoxin** is the prototype P-gp substrate. Co-administration of Verapamil or Ketoconazole with Digoxin can lead to **Digoxin toxicity** due to inhibited renal clearance and increased intestinal absorption. * **Location:** P-gp is encoded by the **MDR1** (Multi-Drug Resistance) gene. Overexpression of this gene in cancer cells is a major cause of resistance to chemotherapy (e.g., Vincristine, Doxorubicin).

Q: Which of the following drugs have a narrow therapeutic index?

All of these. **Explanation:** The **Therapeutic Index (TI)** is the ratio of the dose that produces toxicity to the dose that produces a clinically desired effect ($TI = TD_{50} / ED_{50}$). A **narrow therapeutic index (NTI)** means there is a very small margin between the effective dose and the toxic dose. For such drugs, small fluctuations in plasma concentration can lead to therapeutic failure or severe toxicity, often requiring **Therapeutic Drug Monitoring (TDM)**. * **Lithium (Option A):** Used in Bipolar Disorder, it has an extremely narrow range (0.6–1.2 mEq/L). Levels above 1.5 mEq/L can cause tremors, ataxia, and seizures. * **Phenytoin (Option B):** An antiepileptic that follows zero-order kinetics at higher therapeutic doses. Small dose increments can lead to a disproportionate rise in plasma levels, causing nystagmus and ataxia. * **Tricyclic Antidepressants (Option C):** Drugs like Amitriptyline have significant cardiotoxicity (arrhythmias) and neurotoxicity in overdose, necessitating careful dosing. Since all three drugs require precise monitoring to avoid toxicity, **Option D** is the correct answer. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for NTI Drugs:** "**W**ith **L**ots **O**f **T**he **P**otent **D**rugs, **S**afety **I**s **N**egligible" * **W**arfarin * **L**ithium * **O**ral Hypoglycemics * **T**heophylline/TCAs * **P**henytoin/Pyrimethamine * **D**igoxin * **S**odium Valproate * **I**mmunosuppressants (Cyclosporine) * **N**o (Nitroglycerin) * Drugs with a **high TI** (e.g., Penicillin, Benzodiazepines) are considered safer as their toxic dose is much higher than their effective dose.

Q: All the following drugs undergo metabolism by acetylation EXCEPT?

Phenytoin. **Explanation:** The correct answer is **Phenytoin**. Metabolism by **acetylation** is a Phase II reaction catalyzed by the enzyme **N-acetyltransferase (NAT)**. This pathway is genetically determined, leading to the classification of individuals as "fast" or "slow" acetylators. **Why Phenytoin is the correct answer:** Phenytoin does not undergo acetylation. Instead, it is metabolized in the liver primarily via **Phase I oxidation** (hydroxylation) by the cytochrome P450 system (specifically **CYP2C9** and **CYP2C19**). A unique feature of phenytoin metabolism is that it follows **zero-order kinetics** (capacity-limited metabolism) at therapeutic or high concentrations, making its plasma levels highly sensitive to dose adjustments. **Why the other options are incorrect:** Options A, B, and C are classic examples of drugs metabolized by acetylation. They can be remembered using the mnemonic **"SHIP"**: * **S**ulfonamides (e.g., Sulfadiazine) * **H**ydralazine (Option B) * **I**soniazid (Option A) * **P**rocainamide (Option C) **Clinical Pearls for NEET-PG:** 1. **Drug-Induced Lupus Erythematosus (DILE):** Slow acetylators are at a significantly higher risk of developing DILE when taking Hydralazine, Isoniazid, or Procainamide. 2. **Isoniazid Toxicity:** Slow acetylators are more prone to peripheral neuropathy (due to Vitamin B6 deficiency), while fast acetylators may be more prone to hepatotoxicity due to the rapid formation of the metabolite acetylhydrazine. 3. **Genetic Polymorphism:** Acetylation is the classic example of pharmacogenetic variation in drug metabolism. **High-Yield Mnemonic for Acetylation:** **"SHIP"** (Sulfonamides, Hydralazine, Isoniazid, Procainamide).

Q: What term describes an exaggerated effect of a pharmacological agent on a patient?

Toxicity. **Explanation:** **1. Why Toxicity is the Correct Answer:** **Toxicity** refers to the **exaggerated pharmacological effects** of a drug that occur when its concentration in the body exceeds the therapeutic range. This is usually dose-dependent and predictable based on the drug's mechanism of action. For example, an excessive dose of an anticoagulant like Warfarin leads to bleeding; this is not a new effect, but an exaggeration of its intended pharmacological action. **2. Why Other Options are Incorrect:** * **Idiosyncrasy (Option A):** This refers to a **genetically determined abnormal reactivity** to a drug that is qualitatively different from its known pharmacological action (e.g., Primaquine causing hemolysis in G6PD deficient patients). It is unpredictable and not dose-dependent in the traditional sense. * **Side Effect (Option B):** These are **unavoidable, non-therapeutic effects** that occur at **therapeutic doses**. They are predictable based on the drug’s profile but are not necessarily "exaggerated" versions of the primary effect (e.g., dry mouth with Atropine). **3. NEET-PG High-Yield Clinical Pearls:** * **Therapeutic Index (TI):** The gap between the therapeutic dose and the toxic dose ($TI = TD_{50} / ED_{50}$). Drugs with a "Narrow Therapeutic Index" (e.g., Lithium, Digoxin, Warfarin) require Therapeutic Drug Monitoring (TDM) to prevent toxicity. * **Intolerance:** This is a related term where a patient shows a characteristic pharmacological effect of a drug at a **sub-therapeutic or very low dose** (the opposite of tolerance). * **Type A vs. Type B Reactions:** Toxicity and Side Effects fall under **Type A (Augmented)** reactions (predictable/dose-dependent), while Idiosyncrasy falls under **Type B (Bizarre)** reactions (unpredictable/not dose-dependent).

Question 1

Which of the following drugs is an inhibitor of cytochrome P450 enzymes?

Accepted Answer

Ketoconazole

Answer

Rifampicin

Answer

Phenytoin

Answer

Phenobarbitone

Question 2

Cyproheptadine acts on which of the following receptors?

Accepted Answer

D2

Answer

H1

Answer

Muscarinic

Answer

5HT2A

Question 3

Sufentanil is a/an:

Accepted Answer

Analgesic

Answer

Antibiotic

Answer

Anticholinergic

Answer

Newer antihistaminic

Question 4

What is the primary purpose of pharmacovigilance?

Accepted Answer

To monitor drug toxicity

Answer

To monitor unauthorized drug manufacture

Answer

Monitoring of students

Answer

To check drug costs

Question 5

Which of the following drugs is not metabolized by acetylation?

Accepted Answer

Metoclopramide

Answer

Isoniazid

Answer

Dapsone

Answer

Hydralazine

Question 6

Which of the following is a P-Glycoprotein inhibitor?

Accepted Answer

Ketoconazole

Answer

Rifampicin

Answer

Phenytoin

Answer

Griseofulvin

Question 7

Which of the following statements is true regarding placebos?

Accepted Answer

A placebo is a substance or treatment with no therapeutic effect.

Answer

A placebo is an inert substance used to deliver an active drug.

Answer

Placebos never elicit a physiological or psychological response.

Answer

All patients exhibit a response to a placebo.

Question 8

Which of the following drugs have a narrow therapeutic index?

Accepted Answer

All of these

Answer

Lithium

Answer

Phenytoin

Answer

Tricyclic antidepressants

Question 9

All the following drugs undergo metabolism by acetylation EXCEPT?

Accepted Answer

Phenytoin

Answer

Isoniazid

Answer

Hydralazine

Answer

Procainamide

Question 10

What term describes an exaggerated effect of a pharmacological agent on a patient?

Accepted Answer

Toxicity

Answer

Idiosyncrasy

Answer

Side effect

Answer

None of the above

General Pharmacology — MCQs

General Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?